We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
New medications for weight loss.
- Authors
Murfin, Melissa
- Abstract
The article offers information on mechanism of action, efficacy and safety, side effects, and dosage for 2 new FDA approved drugs for weight loss, "Belviq" and "Qsymia". Belviq containing Lorcaserin, and Qsymia consisting of phentermine and extended-release (ER) topiramate, are intended for use as appetite suppressants. It mentions that FDA awaits postmarketing information on long-term risk of Belviq and a postmarketing evaluation for risk of fetal defects for Qsymia use in pregnancy.
- Subjects
AMPHETAMINES; APPETITE depressants; COMBINATION drug therapy; OBESITY; WEIGHT loss; TOPIRAMATE; DRUG approval; PHARMACODYNAMICS; THERAPEUTICS
- Publication
JAAPA: Journal of the American Academy of Physician Assistants (Haymarket Media, Inc.), 2012, Vol 25, Issue 12, p59
- ISSN
1547-1896
- Publication type
Article
- DOI
10.1097/01720610-201212000-00013